Matrixyl 3000 blend

Last Updated: August 2026

Matrixyl 3000 is a trademarked Sederma peptide blend — not a single molecule. It combines two palmitoylated signal peptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR), both of which have their own Peptigrity profiles. It's the second-generation successor to the original Matrixyl (a single, different peptide), and is one of the most common peptide complexes in anti-aging skincare. It is a cosmetic ingredient, not an approved drug. No independent controlled clinical trial of the Matrixyl 3000 blend itself has been published as of August 2026; the human evidence for its two peptides is largely in-vitro plus manufacturer panels, and the science of each peptide lives on its own page. Matrixyl 3000 sits in Peptigrity’s skin and anti-aging peptides category.

What is Matrixyl 3000 and how does the two-peptide logic work?

The blend targets both sides of the collagen balance: palmitoyl tripeptide-1 (Pal-GHK), a palmitoylated GHK matrikine, signals fibroblasts to build collagen (I, III, IV) and fibronectin, while palmitoyl tetrapeptide-7 (Pal-GQPR) is an anti-inflammatory peptide that suppresses interleukin-6 — a cytokine that both lowers collagen synthesis and drives MMP breakdown of the matrix. In other words, one peptide stimulates synthesis while the other blunts inflammatory degradation, which is the rationale for combining them.

What does the evidence show — and where should you be skeptical?

In-vitro evidence for collagen stimulation is solid, and cosmetic studies report periorbital wrinkle reduction — but this is the key honesty point: much of the widely quoted efficacy figure traces to the manufacturer (Sederma) rather than independent journals, and the independent clinical base is smaller than the marketing implies. A commonly cited manufacturer evaluation (~23 volunteers, 2 months, 3% formulation) reported reductions in wrinkle area and depth versus vehicle — but that figure is manufacturer-generated data, not an independent peer-reviewed trial. The one independent, vehicle-controlled RCT in this family tested the single-peptide original Matrixyl (Pal-KTTKS), not the two-peptide Matrixyl 3000 blend. Treat headline percentages critically and expect a modest, supportive effect. Evidence level: In-vitro solid; clinical base smaller and more manufacturer-associated than marketing suggests.

Is Matrixyl 3000 safe, and how is it different from original Matrixyl?

Matrixyl 3000 is well tolerated in topical use, and the crucial distinction is compositional: original Matrixyl is a single peptide (Pal-KTTKS), while Matrixyl 3000 is the two-peptide (Pal-Tripeptide-1 + Pal-Tetrapeptide-7) blend — to tell which is in a product, read the INCI list. Products marketed simply as "Matrixyl" may contain either, so the INCI declaration is what matters.

Why does raw-material verification matter, and how does Peptigrity verify?

Because Matrixyl 3000 is a blend, the relevant checks are whether both component peptides are present, correctly identified, and at appropriate ratios/purity — HPLC and mass-spec against the two INCI components are the objective test. Peptigrity collects independent third-party Certificates of Analysis for Matrixyl 3000 from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. The trust score weights lab purity and reviews equally (50/50). See how to read lab results.

Educational information only; not medical or skincare advice. Matrixyl 3000 is a cosmetic ingredient blend, not an approved drug — patch-test before use. Peptigrity does not sell, endorse, or recommend products or vendors.